Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Exelixis (EXEL) PT Lowered to $27 at RBC Capital
May 1, 2024 6:30 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Exelixis (NASDAQ: EXEL) to $27.00 (from $28.00) while maintaining a Outperform rating.
The analyst comments "Cabometyx sales were notably lighter than typical though 1Q softness is a trend (also in '22 & '23) and we... More
Exelixis (EXEL) Misses Q1 EPS by 6c, Misses on Revenue
April 30, 2024 4:14 PM EDTExelixis (NASDAQ: EXEL) reported Q1 EPS of $0.17, $0.06 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $425 million versus the consensus estimate of $456.83 million.
GUIDANCE:
Exelixis sees FY2024 revenue of $1.83-1.93 billion, versus the consensus of $1.91... More
